Stay ConnectedThe Brom Podcast covers the emerging psychedelics industry from a business, investing, cultural and social impact perspective. Episodes feature psychedelic CEOs, scientists, investors, and other change-makers operating in the weird, wonderful world of psychedelic medicine.
Brom Rector is the founder and general partner of Empath Ventures, a venture capital fund that invests in early stage startups focused on psychedelic medicine.
Copyright: © Brom Rector and Empath Ventures
🤖 ChatGPT & Dall-E today - misinformation, bias & worker displacement tomorrow. In a world where artificial intelligence is becoming increasingly advanced, it's more important than ever to ensure that AI systems are aligned with our values and behave in ways that are safe for humanity. But what exactly does it mean to align an AI system, and how do we go about ensuring its safety?
Here to answer these questions and more (including the most important question: will AIs take psychedelics?) is Ramsay Brown. Ramsay is the Founder of the AI Responsibility Lab (AIRL). AIRL builds venture-scale deep tech solutions for AI Safety and AI Resilience. AIRL's flagship product, Mission Control, integrates Responsible AI training, AI Risk Management, and AI Governance orchestration to drive fairness, explainability, and trust throughout the entire AI lifecycle.
Check out AIRL here: https://www.takecontrol.ai/
Ramsay on Twitter: https://twitter.com/_ramsaybrown
Brom on twitter: https://twitter.com/therealbrom
5:30 - What are the major concerns in AI safety?
10:30 - Examples of AI gone bad
16:00 - What is the hardest part of AI alignment?
21:00 - What is Ramsay’s unique angle on AI alignment?
24:00 - Is the world ready for conversations about responsible AI?
25:30 - Who is responsible for responsible AI?
32:00 - What regulations would Ramsay put into place?
41:00 - Eliezer Yudkowsky
47:00 - The era of synthetic labor
55:00 - The Turing Test is a red herring
1:04:00 - What jobs are safe from the AI takeover?
1:14:00 - Will machines do psychedelics?
🍄 India Oxenberg is a survivor of the NXIVM cult. While her 7 years in NXIVM have been covered extensively in multiple documentaries, articles and books, this is the first interview in which she details the role that psychedelics played in her post-NXIVM healing journey.
India is the author of "Still Learning", a memoir documenting her seven-year experience with and escape from the toxic cult, NXIVM. She is the executive producer of "SEDUCED: INSIDE THE NXIVM CULT", a Starz documentary. By sharing her story, she hopes to raise awareness about the insidious nature of coercion and hopes to offer other survivors a platform to share their stores.
India's mother, Catherine Oxenberg was instrumental in taking down NXIVM. She is the founder of The Catherine Oxenberg Foundation, a foundation dedicated to helping individuals and families recover from the devastating effects of unresolved trauma. Their mission is to shift the paradigm of trauma from one of stigma and disability to one of growth, opportunity and a gateway to wisdom and empowerment.
Keith Raniere, the founder of NXIVM was found guilty of sex trafficking, racketeering, wire fraud and a litany of other charges in 2019. He is currently serving a 120 year prison sentence.
Follow India on Instagram: https://www.instagram.com/indiaoxenberg/
The Catherine Oxenberg Foundation: https://catherineoxenberg.com/foundation/
Follow Brom on Twitter: https://www.twitter.com/therealbrom
⏰ Timestamps
01:36 India's time in NXIVM
21:52 How did psychedelics become a part of India’s healing journey?
34:00 Advice from India to other women who’ve experienced sexual trauma
38:16 How psychedelics healed India’s relationship with her family
41:17 Other substances that India experimented with
45:00 Self-guided VS Guided trips?
48:50 How psychedelics helped India see Keith Raniere in a different light
54:12 Bad trips: ketamine nightmares
58:45 Trying psychedelics while being in a cult
1:07:58 Psychedelic cults and how to identify them
🍄 Today’s guest is William-Padilla Brown. William is a self-taught mycologist, mushroom forager, and researcher. He’s the founder of MycoSymbiotics, a research organization focused on Fungi and Algae.
In this episode:
- How cordyceps can inhibit HIV
- Why you should grow oyster mushrooms on coffee grounds
- The most over-looked functional mushroom
- How mushrooms can absorb radiation
- Fun theories about psychedelic algae
- Meta-Programming the human biocomputer
- And More!
Learn more about Will on his website: https://solo.to/permaculturepapi
Learn more about Mycosymbiotics on the website: https://mycosymbiotics.com/
Follow Brom on Twitter: https://www.twitter.com/therealbrom
Invest in Brom's VC Fund, Empath Ventures: https://www.empath.vc
⏰ Time Stamps:
0:00 Why are mushrooms having a moment?
10:00 How did Will get into mushrooms?
18:20 How to get started with mushrooms/mycology/foraging
26:03 Are there significant differences between different strains of psychedelic mushrooms?
29:57 What compounds, other than psilocybin, can impact your psychedelic trip?
35:36 Cordyceps: the mushroom that grows on insects
41:49 What do cordyceps do to the human body and why should we consume them?
46:56 What mushrooms should beginning growers start with
48:03 What is the most underrated functional mushroom?
53:04 Algae?
59:45 Meta programming the human biocomputer
1:02:05 Industry prediction in Oregon and Colorado
Today’s guest is Raad Seraj, Raad is a technologist, angel investor, artist, and advocate for emerging mental health therapies including psychedelics. Raad recently launched his podcast, Minority Trip Report (MTR), to discuss under-represented views and life journeys with mental health, psychedelics, and consciousness.
Learn more about Raad on his website: https://raadseraj.com/about-me
Listen to his podcast: https://www.minoritytrip.com/
🍄 Today’s guest is Samantha Tabone. Sam is a Partner at Empath Ventures where she leads in-depth technical and scientific due diligence on Empath’s psychedelic biotech investments. Sam is here to help break down the due diligence process Empath uses when evaluating potential investments in psychedelic biotech companies. Empath's Due Diligence process is broken down into 4 pillars: Team, Intellectual Property, Scientific Foundations and Operations / Strategy.
Prior to Empath, Sam served as the VP of R&D for PurMinds, a neuromedicine startup developing novel therapeutics for neurodegenerative diseases. As an independent consultant she’s led projects for leading psychedelic companies including Beckley Psytech, advised family offices on Life Science investment strategies, and worked as a temporary strategic director at several biotech startups. Sam has been fascinated with neuroscience and psychedelics (especially DMT) since she was in her teens. She’s most excited about funding psychedelic startups working towards solutions for complex neurological disorders. She holds a B.S. in Chemistry from the University of Toronto and attended the University of Wisconsin-Madison’s Pharmaceutical Sciences Master’s program.
🔗 Connect with Sam on LinkedIn: https://www.linkedin.com/in/samanthatabone/
🐦 Follow Brom on Twitter: https://www.twitter.com/therealbrom
🍄 Empath Ventures: https://www.empath.vc
Make sure to subscribe to the show!
Lack of authentic human connection is one of the biggest problems facing society. Can psychedelics deepen our relationships, strengthen our communities and help us have better sex? Dr Molly thinks that the answer just might be "Yes".
In this episode:
- battling the stigmas around sex and drugs
- how psychedelics can improve your sex life
- the risks of falling in love with an AI boy/girl friend
Follow Dr Molly at https://drmolly.co/
Check out Brom's VC fund at https://www.empath.vc
Make sure to subscribe to the show!
Schedule35 sells psilocybin mushrooms online in the US and Canada (yep, you heard that right). Their branding is amazing and they advertise on mainstream podcasts like Hotboxin' with Mike Tyson - where I first heard of them.
Leon, the founder of Schedule35 joins Brom today to tell us:
- how he got into microdosing and started Schedule35
- what it takes to run an online psilocybin business in the current regulatory environment
- his views on pharma / medicalized psychedelics VS recreational psychedelics
Make sure to subscribe to the show!
Check out Schedule35 at schedule35.co
Check out Brom's VC fund at empath.vc
The Brom Podcast covers the emerging psychedelics industry from a business, investing and social impact perspective.
Episodes feature Empath Ventures' Founder, Brom Rector interviewing psychedelic CEOs, scientists, investors, and other change-makers operating in the weird, wonderful world of psychedelic medicine.
The Brom Podcast is available on all platforms!
Music from Uppbeat (free for Creators!):
https://uppbeat.io/t/sky-toes/desert-flower
License code: JIRV6GGWC28YEPJH
Rebecca Nicholson is the CEO of 5D World and Founding partner of 5D Ventures. Unlike other psychedelic VCs that focus on biotech, 5D’s “Progression of Consciousness Fund” is the only psychedelic fund focused on investing in psychedelic retreats. Rebecca joins the Brom podcast to discuss:
- her views on investing in retreats
- the difference between retreats and clinics
- her own experience at some of these retreats - including tripping with Amanda Feilding
- the importance of the feminine perspective in the psychedelic industry.
Make sure to subscribe to the show!
Check out 5d world at: https://www.5dworld.com/
Follow Brom on Twitter: https://www.twitter.com/therealbrom
Brom's Venture Fund: https://www.empath.vc
Zach Haigney is the author of The Trip Report, a newsIetter that covers the emerging psychedelic science, medicine, and policy landscape. In this conversation, Zach and Brom discuss emerging trends, questions and hot topics in the psychedelics industry including:
We also discuss The Trip Report's recent acquisition by Beckley Waves.
You can check out The Trip Report here: https://thetripreport.substack.com/
Follow Zach on Twitter: https://twitter.com/zach_haigney
Follow Brom on Twitter: https://twitter.com/therealbrom
Make sure to subscribe to the show!
Sam Banister is a medicinal chemist and co-founder of Psylo. Psylo is an Australian psychedelic biotech company using machine learning assisted drug design techniques to developing novel psychedelic medicines to treat mental illness.
Sam is here to help us understand how new chemical entities are reshaping the psychedelic field; how novel psychedelic molecules are made, and how new chemical entities are going to play a dominant role in the future of psychedelic medicine.
Make sure to subscribe to the show!
Follow Brom on twitter: https://twitter.com/therealbrom
Follow Sam on twitter: https://twitter.com/samuel_b_phd
Brom's VC Fund: https://www.empath.vc
Highlighted Timestamps:
06:12 - Are next generation psychedelics taking over in 10 years?
16:10 - What is the process like for creating a new chemical entities?
50:39 - Psychedelics vs Cannabis: New drug discoveries
Patrick Moher is the President of Microdose.buzz, the leading psychedelic industry website. He joins Brom today to discuss his personal history with psychedelics, his views on the future of the industry, what it was like talking about psychedelics at Davos, and gives us a preview of what's to come at Wonderland Miami 2022.
Tickets for Wonderland Miami 2022 are on sale now: https://tickets.microdose.buzz/attendance/event/index/41737/EN
Mendel Kaelen is the CEO of Wavepaths. Prior to founding Wavepaths, Mendel Kaelen worked as a PhD and postdoctoral neuroscientist at Imperial College London since 2012, where his research was the one of the first to demonstrate music’s central role in psychedelic therapies. Wavepaths is a software platform that generates personalized, optimal music for psychedelic therapy.
0:00 - Why work on music and psychedelics?
3:30 - Highlights of Mendel’s academic career.
7:30 - Is there a universal “best” music for psychedelic therapy? How to design a psychedelic therapy playlist.
11:30 - What does the importance of music personalization mean for group psychedelic sessions?
16:00 - Should music for psychedelics be “familiar” to the patient, or novel?
20:00 - Vocals vs no vocals? It’s not that simple.
23:00 - Directive vs non-directive and concrete vs fluid music.
25:00 - Is the “right” music for psychedelics consistent across different drugs?
28:00 - How did Mendel switch from academia to startup founder.
30:30 - What is Wavepaths?
35:30 - Who is Wavepaths for?
37:00 - How do you sell music for psychedelic therapy?
39:00 - Surprising insights from Wavepaths customers?
43:30 - How does Wavepaths use biofeedback?
46:00 - Wavepaths direct to consumer.
49:45 - Startup life vs academia.
51:00 - Virtual reality and psychedelic therapy.
tmp
Joe Moore is the CEO & Co-Founder of Psychedelics Today - the largest and longest running podcast and media operation in psychedelics. In this episode, Joe and I discuss the hottest topics in psychedelics: Joe Rogan, the dark forces at work in the psychedelics industry, the problem with decriminalization and amongst many other things, we speculate on how fermentation could put the drug cartels out of business (cocaine kombucha anyone?). And of course, we touch on Psychedelics Today's new training program - Vital: https://www.vitalpsychedelictraining.com/
This is an episode you don't want to miss.
Joe earned a B.A. at Plymouth State University in Philosophy and has been studying psychedelics since 2001. After working for 20 years in software, Joe is dedicated to working towards improved drug policy and greater inclusion of psychedelics in culture. In 2016, Joe co-founded Psychedelics Today, a world-leading psychedelic education and media platform. The popular Psychedelics Today podcast has been downloaded over 2.4-million times, and the Psychedelics Today Psychedelic Education Center has enrolled over 9,000 students in psychedelic training e-learning courses.
🎧 Listen to Psychedelics Today: https://psychedelicstoday.com/
💰 Check out Brom's psychedelic VC fund: https://www.empath.vc
⏰ Timestamps:
0:00 - intro and Joe’s background + meeting Stan Grof & Graham Hancock + Joe’s old podcast: Occult Sentinel
6:30 - we talk about Joe Rogan
8:00 - the drug war / DEA and how it impacts drug development
12:00 - the dark forces and shady actors playing in the psychedelics industry
18:00 - Vital: the Psychedelics Today psychedelic guide training program
25:30 - psychedelic pharma vs recreational & decrim + more on the drug war
31:00 - Joe’s take on Decriminalize Nature, or as he would call it: Decriminalize Some Nature
36:00 - could genetically engineered yeast and biofermentation defund cartels and end the drug war?
39:00 - the bipartisan support behind psychedelic policy reform + could Texas be the center of the psychedelic revolution?
41:30 - Joe’s views on the ethical challenges of psychedelic capitalism
48:00 - What’s going on in Oregon with Measure 109?
50:00 - are Psychedelic Assisted Experiences the next wave of the industry?
51:00 - How has decrim impacted Denver?
55:00 - Joe’s cautious take on the outlook for psychedelic businesses + competition from decrim and religious groups (Psychedelic Episcopalians?)
Tom Feegel is the Founder and CEO of Beond. Beond exists to help end the opiate addiction epidemic with safe ibogaine treatment.
In this episode Tom speaks on the severity of the opioid epidemic and explains how ibogaine assisted therapy can help heal those who are suffering from addiction. Tom gets into his personal story, how Ibogaine helped someone in his family, the economics of addiction treatment and Beond's plans to scale into a global operation.
➡️ Follow Beond: https://www.beond.us
💸 Invest with Brom: https://www.empath.vc
⏰ Timestamps:
🚨 Disclosure: Empath Ventures is an investor in Beond.
Mycrodose's CEO Chad Conner and CSO Frank Kochinke return to the podcast to tell us about:
⭐️ Follow Mycrodose: https://mycrodosethera.com/
🔥. Follow Brom: https://www.twitter.com/therealbrom
⏰ Timestamps:
Dillan DiNardo is the CEO of Mindstate Design Labs - a preclinical-stage biotechnology company developing the next generation of psychedelic-inspired therapeutics for intractable mental health conditions.
Mindstate's mission is to map the biological basis of the varieties of psychedelic experience, and to use that map to pharmacologically design therapeutic states of mind to be applied in medically supervised settings to heal the root causes of mental health disorders. Mindstate participated in Y Combinator in 2021.
Brom's Psychedelic VC fund, Empath Ventures is an investor in Mindstate.
Check out Mindstate @ https://www.mindstate.design/
Mental health treatment is often inaccessible, inadequate, and ineffective. However, Nue Life is working to change this through its 360-degree approach to patient health, leveraging ketamine and the integration of tech.
Check out Nue.Life here: https://nue.life/
⏰ Timestamps:
0:00 intro and Juan Pablo’s backstory
5:30 how Nue Life got started
11:00 the Nue Life patient experience
20:40 the intersection of data and mental health
32:30 competition in the Ketamine landscape
37:00 is ketamine addictive?
45:00 the future of at-home ketamine and the Ryan Haight act
49:15 legal psilocybin in Oregon?
53:30 what’s next for Nue Life?
Eesmyal Santos-Brault & Dr. Pamela Kryskow from Quantified Citizen talk about Quantified Citizen the app, and the results of Quantified Citizen's first study: Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers.
Check out the paper here: https://www.nature.com/articles/s41598-021-01811-4
💰 Invest in Brom's Psychedelic VC Fund: https://www.empath.vc
The Integration Conversation is BACK with Nadia van der Heyden, Director of Sales and Marketing at Psygen.
Recorded at Wonderland Miami.
💰 Invest in Brom's Psychedelic VC Fund: https://www.empath.vc
🐦 brom on twitter: https://twitter.com/therealbrom
💌 Email: hello@empath.vc
Brom discusses 10 interesting startup ideas for entrepreneurs in the psychedelics space.
The ideas include applications of psychedelics to non mental health disorders, sexual disfunction, anti-aging, digital addiction, crypto, non-5ht2a drugs, gender specific issues, sustainable manufacturing and digital therapeutics.
If you're an entrepreneur working on a psychedelic startup, we'd love to hear from you. Please contact us at hello@empath.vc
💰 Invest in Brom's Psychedelic VC Fund: https://www.empath.vc
📺 Watch on YouTube: https://youtu.be/rpK8tzv2AaM
Mycrodose Therapeutics is a US-Based pharmaceutical company specializing in the development of Advanced Drug Delivery (ADD) systems for psychedelic compounds. In this episode of The Integration Conversation, Mycrodose's Chad Conner and Patrick Eckstrom join Brom to discuss how ADD systems can potentially improve the patient experience, increase the safety profile and lower the cost of psychedelic drugs.
💰 Invest in Brom's Psychedelic VC Fund:
📺 Watch on YouTube:
https://youtu.be/HmBsrUQYyOg
🐦 brom on twitter:
https://twitter.com/therealbrom
🎇 Clips and other stuff on Instagram:
https://instagram.com/theintegrationco
💌 Email:
hello@empath.vc
Todd Shapiro is the CEO of Red Light Holland ($TRIP, $TRUFF), the only publicly traded company focused on recreational psychedelics. In this episode of The Integration Conversation, Todd explains the history of Red Light Holland, speculates on timelines for when Red Light Holland will be able to sell in the US, and tells us about Red Light Holland's foray into Virtual Reality and consumer products like the Wisdom Truffle.
And of course, we ask the big question: Is Red Light Holland Undervalued?
---
❤️ Invest in Brom's Psychedelic Venture Capital Fund:
https://www.empath.vc
📺Watch on YouTube:
https://youtu.be/1OzpNIQDkyI
⚠️Disclaimer:
This content is not financial advice. Brom holds shares in Red Light Holland
Negev Capital is a VC fund focused on psychedelic medicine.
In this episode of The Integration Conversation, Ken Belotsky and Stuart Seidman tell us about Negev's founding, its strategy, and what it's like to run a venture fund in the psychedelics space.
❤️ Help us fund the future of psychedelic medicine at Empath Ventures: https://www.empath.vc
⭐️ Become an Integration Insider and get early access to episodes: https://patreon.com/theintegrationco
🐦 brom on twitter:
https://twitter.com/therealbrom
🎇 Clips and other stuff on Instagram:
https://instagram.com/theintegrationco
⏰ Timestamps:
0:45 - Ken & Stuart’s backgrounds
6:00 - what is it like raising money for a Psychedelic Venture Fund?
14:00 - what is Negev’s focus?
19:30 - how do you do due diligence?
23:30 - do novel psychedelics replace the classic psychedelics in the long run?
26:30 - what are the developing trends in psychedelics?
37:30 - is there too much capital in the space?
Jack Swain is the Head of Clinical Operations at Mindbloom, the world's largest telemedicine based ketamine clinic. In this episode of The Integration Conversation, Jack talks about what it's like to be involved in a rapidly growing psychedelic startup, the differences between in-clinic and telemedicine based ketamine therapy, and how Mindbloom will scale to other psychedelic drugs like psilocybin and MDMA.
❤️ Help us fund the future of psychedelic medicine at Empath Ventures:
📺 Watch on YouTube:
https://youtu.be/HskAmw27a-M
⭐️ Become an Integration Insider and get early access to episodes:
https://patreon.com/theintegrationco
🐦 brom on twitter:
https://twitter.com/therealbrom
🎇 Clips and other stuff on Instagram:
https://instagram.com/theintegrationco
disclaimer: this is not financial advice
Paul Kohlhaas is the cofounder of Molecule ( https://molecule.to/ ) a collaborative platform where stakeholders in drug development work together to accelerate the process of bringing novel therapeutics to patients. He is also the co-initiator of VitaDAO ( https://www.vitadao.com/ ), a decentralized collective funding early stage longevity research. In this episode we discuss the exciting intersection of crypto and biotech, and how DAOs might replace some of the traditional funding mechanisms of scientific research.
❤️ Help us fund the future of psychedelic medicine at Empath Ventures: https://www.empath.vc
Bruce Linton is a legend in the cannabis and psychedelics industries. He was the CEO of the world's largest cannabis company (Canopy Growth), was the first investor in MindMed, and is Chairman of the Advisory Board at Red Light Holland.
Bruce joins The Integration Conversation to answer questions like:
And more!
Plus, Brom and Bruce talk about Empath Ventures.
❤️ Help us fund the future of psychedelic medicine at Empath Ventures:
⭐️ Become an Integration Insider and get early access to episodes:
https://patreon.com/theintegrationco
🐦 brom on twitter:
https://twitter.com/therealbrom
🎇 Clips and other stuff on Instagram:
https://instagram.com/theintegrationco
Disclaimer / Disclosure: This is not financial advice. Brom owns shares in MindMed, Red Light Holland and other psychedelics stocks.
🍄 Bright Minds Bio is a psychedelics research company focused on novel psychedelics with shorter trip times and lower risk than traditional psychedelics. In this episode of The Integration Conversation, we discuss the risk of traditional psychedelics, what a 5HT2C agonist is, Bright Mind's NASDAQ Uplisting, and discuss why Bright Minds might be undervalued relative to its peers.
⭐️ Become an Integration Insider and get early access to episodes:
https://patreon.com/theintegrationco
🎧 Listen on Spotify and other podcast platforms:
https://anchor.fm/theintegrationco
🐦 brom on twitter:
https://twitter.com/therealbrom
🎇 Clips and other stuff on Instagram:
https://instagram.com/theintegrationco
💌 Email:
bromtalks@pm.me
⏰ Timestamps:
Disclaimer: This video is not financial advice. Brom holds shares in Bright Minds.
🍄 Josh Bartch is the CEO of Mydecine Innovations Group, a psychedelics company that is researching naturally sourced psychedelic therapeutics targeting PTSD and smoking cessation. In this episode of The Integration Conversation, Josh joins us for a full hour and tells us about Mydecine's clinical trials, its research on functional mushrooms, and makes his pitch for why Mydecine is undervalued relative to its peers.
Questions we answer:
🔥 Invest in Psychedelic Startups with Us 🔥
go to https://theintegration.co and click on "invest in psychedelic startups"
The Integration Conversation is a podcast that covers the emerging psychedelics industry from a business perspective, and aims to be your number 1 resource for investing in psychedelics, psychedelic investing and psychedelic business.
⛓ All our links:
https://theintegration.co
📝 My notes on psychedelic investing:
https://brompersonal.s3-us-west-2.amazonaws.com/assets/broms-notes-psychedelic-investing.pdf
🎧 Listen on Spotify and other podcast platforms:
https://anchor.fm/theintegrationco
🐦 brom on twitter:
https://twitter.com/therealbrom
🎇 Clips and other stuff on Instagram:
https://instagram.com/theintegrationco
⏰ Timestamps:
Disclaimer: This video is not financial advice. Brom holds shares in Mydecine and other psychedelic stocks.
What exactly is psychedelic therapy, and what does the research on psychedelic therapy tell us about its effectiveness?
In this episode of The Integration Conversation, Brom provides a description of what exactly happens during psychedelic therapy, and then goes over the three most compelling clinical research papers on psychedelic therapy.
Learn about how MDMA can treat Post Traumatic Stress Disorder, psilocybin can treat depression, and how psilocybin stacks up against SSRIs like Lexapro.
👇 studies mentioned in this video
MDMA for PTSD https://www.nature.com/articles/s41591-021-01336-3
Trial of Psilocybin versus Escitalopram for Depression
https://www.nejm.org/doi/full/10.1056/NEJMoa2032994
Psilocybin to treat Depression and Anxiety in Cancer patients
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367557/
Psilocybin for smoking Cessation
https://files.csp.org/Psilocybin/Johnson2017Smoking.pdf
Ibogaine for Opioid Dependence
https://pubmed.ncbi.nlm.nih.gov/28402682/
In this episode of The Integration Conversion, brom give a broad overview of the psychedelic investing landspace, and addresses come common misconceptions about investing in psychedelics.
Topics Include:
We answer these questions and more - enjoy 🍄
📺 Watch on YouTube:
https://youtu.be/JsFoA0GyKxI
📝 My notes on psychedelic investing:
https://brompersonal.s3-us-west-2.amazonaws.com/assets/broms-notes-psychedelic-investing.pdf
🎧 Listen on Spotify and other podcast platforms:
https://anchor.fm/theintegrationco
🐦 brom on twitter:
https://twitter.com/therealbrom
🎇 Clips and other stuff on Instagram:
https://instagram.com/theintegrationco
💌 Email:
bromtalks@pm.me
⏰ Timestamps:
I'm experimenting with a weekly livestream format where I respond to short psychedelic articles / topics that don't warrant an entire video. Plus I interact with the viewers and answer their questions about any psychedelic topics.
🍄 Doug Drysdale is the CEO of Cybin, a psychedelic research company developing novel delivery systems for psilocybin, next-gen psychedelic tryptamine molecules and performing studies on human brains under the influence of psychedelics using powerful brain imaging technology. In this episode of the Integration Conversation, Brom and Doug cover all aspects of Cybin's business, and answer questions like:
👇👇👇 Links 👇👇👇
📺 Watch on YouTube: https://youtu.be/cAsFHlVLpeA
💻 The Integration Co Website: https:/theintegration.co
📝 My notes on psychedelic investing: https://brompersonal.s3-us-west-2.amazonaws.com/assets/broms-notes-psychedelic-investing.pdf
🎧 Listen on Spotify and other podcast platforms: https://anchor.fm/theintegrationco
🐦 brom on twitter: https://twitter.com/therealbrom
🎇 Clips and other stuff on Instagram: https://instagram.com/theintegrationco
💌 Email: bromtalks@pm.me
⏰ Timestamps:
Disclaimer: This video is not financial advice. Brom holds shares in Cybin, Field Trip Health, Mind Med, Cybin and Compass Pathways.
🍄 Field Trip Health is the largest publicly traded, vertically integrated psychedelics company on the market. Field Trip has a rapidly growing network of ketamine clinics and is developing novel psychedelic molecules and digital therapeutics. In this deep dive episode, we interview Ronan Levy, the cofounder and executive chairman of field trip. Ronan tells us:
📺 Watch the video on YouTube: https://youtu.be/8gtyZ8DWwNo
📝 My notes on psychedelic investing: https://brompersonal.s3-us-west-2.amazonaws.com/assets/broms-notes-psychedelic-investing.pdf
🎧 Listen on Spotify and other podcast platforms: https://anchor.fm/bromtalks
🐦 brom on twitter: https://twitter.com/therealbrom
🎇 Clips and other stuff on Instagram: https://instagram.com/bromtalks
💌 Email: bromtalks@pm.me
Disclaimer: This video is not financial advice. Brom holds shares in Field Trip Health, Mind Med, Cybin and Compass Pathways.
Atai Life Sciences is the most highly anticipated psychedelic IPO of 2021. It has a pipeline of 10 drugs, owns a large piece of Compass Pathways, and is also researching digital therapeutics and brain computer interfaces. When it IPOs it will likely be the psychedelic company with the largest market cap. In this episode of Brom Talks, we peek behind the curtain of Atai, and try to see if this valuation is justified. In doing so, we answer questions like:
Who is Christian Angermayer? What does Atai's pipeline look like? What are the implications of Atai's unorthodox corporate structure? It is even fair to call Atai a psychedelics company? And we also compare and contrast this company with MindMed.
📝 My notes on psychedelic investing:
https://brompersonal.s3-us-west-2.amazonaws.com/assets/broms-notes-psychedelic-investing.pdf
🎧 Listen on Spotify and other podcast platforms:
https://anchor.fm/bromtalks
📺YouTube:
https://www.youtube.com/c/bromtalks
🐦 brom on twitter:
https://twitter.com/therealbrom
🎇 Clips and other stuff on Instagram:
https://instagram.com/bromtalks
💌 Email:
bromtalks@pm.me
🍄 Wondering how to tell if a psychedelic stock is legit or full of shit? This video describes how to research and understand both the psychedelic sector as a whole and individual psychedelic companies. First we walk through my notes on investing in the psychedelic sector, and then look at 10 questions you should ask before investing in any psychedelic company. We show how to use these questions to compare and contrast different psychedelic companies, and apply this methodology to Mind Medicine, Compass Pathways and Cybin.
My notes on psychedelic investing: https://brompersonal.s3-us-west-2.amazonaws.com/assets/broms-notes-psychedelic-investing.pdf
Google Spreadsheet containing the 10 questions:
https://docs.google.com/spreadsheets/d/1KIp_nd-OhyU5xx63oEMsKgU3XFZkkItl-aoyjCdItkg/edit?usp=sharing
CLARIFICATIONS / CORRECTIONS
📺 Watch on YouTube: https://youtu.be/oA85Xzms8_U
🎇 Clips and other stuff on Instagram: https://instagram.com/bromtalks
🐦 brom on twitter: https://twitter.com/therealbrom
⏰Timestamps:
Disclaimer: This presentation is not financial advice. You should not make any investment or trading decision based on the contents of this presentation. Do not consider anything in this presentation to be professional advice. Brom holds long positions in MindMed, Compass and Cybin as well as other psychedelic stocks.
🚀 Are you degen trader that's down 50% on a MindMed yolo? I'm your stock therapist and I'm here to help you understand your emotions. In this video I go over some basic behavioral economic concepts (like utility theory, risk aversion and risk seeking) and demonstrate how they apply to the psychology of traders using MindMed as a case study.
Questions answered:
Watch the vid @ https://youtube.com/c/bromtalks
🍄 Cybin Corp / Cybin Inc is a Psychedelics 2.0 company focused on new innovations in psychedelic drugs. In this episode of Brom Talks, we investigate the Cybin team, go over their business lines, see what sets them apart from other psychedelic companies like MindMed and Compass. We also answer questions like:
Watch on YouTube: https://linktr.ee/therealbrom
Disclaimer: This presentation is not financial advice. You should not make any investment or trading decision based on the contents of this presentation. Do not consider anything in this presentation to be professional advice. Brom holds long positions in Cybin as well as other psychedelic stocks.
🍄 Compass Pathways is the largest psychedelic stock by market cap, and was famously backed by Paypal and Palantir Founder Peter Thiel. In this episode I investigate Compass Pathways and answer questions like:
📺Watch on YouTube:
https://youtu.be/ha2GMoZ7s60
📹 Clips Channel:
https://www.youtube.com/channel/UCDzauugr4QA5dfcwaE1rweQ
🎇 Clips and other stuff on Instagram:
https://instagram.com/bromtalks
🐦 brom on twitter:
https://twitter.com/therealbrom
Disclaimer: This recording is not financial advice. You should not make any investment or trading decision based on the contents of this recording. Do not consider anything in this video to be professional advice. Brom holds long positions in Compass Pathways as well as other psychedelic stocks.
What is the true market cap potential for the medicinal psychedelic industry, and what's the best way to ride the shroom boom and invest in the psychedelic sector? I show three different market cap estimates, discuss various pitfalls and caveats, and give my thoughts on how best to invest in this space. Watch the video: https://youtu.be/jb949AKsYAA
Today we go deep into Numinus Wellness. Numinus (also known as Numi) is a Canadian Psychedelic startup that many people think is undervalued. This episode looks into this claim and tries to answer questions like:
You can watch this episode on YouTube https://youtu.be/jg2H0sMHZXg
See Brom's other links https://linktr.ee/therealbrom
Disclaimer: This video is not financial advice. Do you own research before buying or selling any stock, and talk to a financial advisor whos incentives are aligned with your own. Brom owns shares of Numi as well as other psychedelic companies.
This is part two of my MindMed Deep Dive. The primary focus of this video is an analysis of MindMed's acquisition of HealthMode. I also clear up a few things from the last video. Did the HealthMode acquisition make sense for MMED? What are their true AI / ML capabilities? Did I sell any shares after the last video? Clarification on my opinion on Departures Capital. Watch the video here: https://youtu.be/LUnEIRZmegE
Part 1 is here (https://youtu.be/cfqdvm_Bz-w).
Many of us have already 10x'd our money on MindMedicine (MMED / MMEDF): should we take our profits now or hold for the next 10 years? Brom dives deep into this topic and looks at questions like:
Watch on YouTube
https://www.youtube.com/playlist?list=PLSojjMXxr79FMrXF5ocZ5Qy5uEQ78FQJG
Listen to this video on Spotify:
https://open.spotify.com/show/1nVnMFaYNmln6fwk63B9kd
Listen to this video on other Podcast Platforms:
https://anchor.fm/brom1
Brom on Instagram:
https://www.instagram.com/brom_qr/channel/
Brom on Twitter:
https://twitter.com/therealbrom
Brom's personal website:
https://brom.ai
We talk the future of psychedelics: decriminalization & legalization. Biotech & Pharma research, Compass Pathways (CMPS), Mind Medicine (MMED / MMEDF), Field Trip Health (FTRP) on substances like LSD, Psilocybin, Ibogaine, etc.
Our TOPPODCAST Picks 
